Localized Prostate Cancer

Treatment approaches covered
Watchful waiting | Active surveillance | Prostatectomy | External beam radiation therapy | Brachytherapy
Androgen Deprivation Treatment | Focal therapy | Other

Details
1 Recorded via the Clavien-Dindo-Classification
2 Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
3 Recommended to track via the Expanded Prostate Cancer Index Composite (EPIC 26 version preferred)

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/Localized-Prostate-Cancer

© 2023 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM as the source so that this organization can continue its work to define more Sets of Patient-Centered Outcome Measures. Version 4.1.0 Revised February 2023
Contributors
For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsor

The Working Group

Australia
Kim Moretti | South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC), The Queen Elizabeth Hospital
Mark Frydenberg | Prostate Cancer Registry of Victoria, Monash University
Ian Roos | Melbourne Graduate School of Education, University of Melbourne, Cancer Action Victoria

Germany
Hartwig Huland & Markus Graefen | Martini-Klinik at University Medical Center Hamburg-Eppendorf
Michael Froehner | University Hospital Carl Gustav Carus, Technical University of Dresden
Gunter Feick* | Bundesverband Prostatakrebs Selbsthilfe (BPS), Europa UOMO
Thomas Wiegell | University Hospital Ulm

Ireland
Frank Sullivan | Galway University Hospital; Prostate Cancer Institute at NUI Galway
John Fitzpatrick | Irish Cancer Society

Israel
Jacob Ramon | Sheba Medical Center

Italy
Alberto Briganti | Vita-Salute San Raffaele University Hospital

Netherlands
Chris Bangma | Erasmus Medical Center

Sweden
Anna Bli-Axelson | Uppsala University Hospital; National Prostate Cancer Register (NPCR) of Sweden

United Kingdom
Adam Glaser | Leeds Teaching Hospitals NHS Trust

United States
James Catto | Academic Urology Unit and Academic Unit of Molecular Oncology, CR-UK/YCR Sheffield Cancer Research Centre
Steven Jay Frank | MD Anderson Cancer Center
David Swanson | MD Anderson Cancer Center
Andrew Vickers | Memorial Sloan-Kettering Cancer Center
Adam Kibel | Dana-Farber Cancer Institute, Brigham and Women's Hospital
Anthony D'Amico | Dana-Farber Cancer Institute, Brigham and Women's Hospital
Neil Martin | Dana-Farber Cancer Institute, Brigham and Women's Hospital
Michael Blute | Massachusetts General Hospital
Howard Sandler | Cedars-Sinai Medical Center
Nancy Mendenhall | University of Florida Proton Therapy Institute
Ronald Chen | University of North Carolina Lineberger Comprehensive Cancer Center
Daniel Hamstra | University of Michigan Health System
Ashutosh Tewari | Icahn School of Medicine at Mount Sinai Hospital

*Patient representative